SEINE BIO · PEPTIDE PROFILE
Tesamorelin
Growth-hormone signaling · a specific HIV-related indication
Approved productGet to know the name, understand the evidence, and prepare a more informed conversation.
What is Tesamorelin?
Egrifta SV is indicated to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. That specific use does not establish it as general weight-loss or anti-aging treatment. Its labeling includes important contraindications and monitoring considerations.
THE FULL READING GUIDE · UPDATED OCTOBER 7, 2026
Inside the science of Tesamorelin.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is available only where lawful for the specific substance and patient. Approved finished medicines may also be dispensed by licensed non-compounding pharmacies; this disclaimer does not establish access to any investigational product.
Overview
Tesamorelin is a growth-hormone-releasing hormone analog with an approved role in reducing excess abdominal fat in adults with HIV-associated lipodystrophy. That indication is more specific than general fat loss. It provides a starting point for an informed discussion about body-fat distribution, HIV care and the difference between a medical diagnosis and an appearance goal.
Community Use
PeptideDosages and Peptidepedia describe tesamorelin in community and performance contexts. Those sources are informal publishers. Their vial-based schedules should not be treated as the instructions for Egrifta, nor as evidence that a general fitness or anti-aging use has the same support.
Doses, Durations & Cycles
Published dosing regimens. Product-label and study regimens for education, not instructions for self-treatment. Product, indication and route matter.
| Route / formulation | Dose / reported phases | Frequency | Duration / break | Notes and source |
|---|---|---|---|---|
| Subcutaneous | 1.28 mg daily | Daily | Ongoing treatment for HIV-associated lipodystrophy; no fixed cycle Break: No routine cycling interval | FDA prescribing information EGRIFTA WR |
| Subcutaneous | 1.4 mg daily | Daily | Ongoing treatment for HIV-associated lipodystrophy; no fixed cycle Break: No routine cycling interval | FDA prescribing information EGRIFTA SV |
Important context: WR and SV doses are formulation-specific; neither is a general weight-loss regimen.
Sources checked October 7, 2026. Educational listing does not establish prescribing approval or availability through Seine Bio.
The chart keeps approved-product and informal source rows separate. Egrifta SV’s label and the 2025 Egrifta WR label have formulation-specific instructions. Matching the molecule’s name does not make their quantities interchangeable. A provider and pharmacy must identify the exact prescribed product.
Research Findings
The approved-product evidence concerns visceral abdominal fat in HIV-associated lipodystrophy. Its endpoints should not be relabeled as a general weight-loss trial or a study of bodybuilding performance. The distinction also changes which specialist, monitoring and other treatments need to be part of the care conversation.
U.S. Approval & Access
Tesamorelin has approved prescription formulations, but the label explicitly says Egrifta SV is not indicated for weight-loss management. DailyMed lists DEA Schedule: None. Being unscheduled does not authorize an unofficial research preparation or guarantee an appropriate prescription.
What It Does in the Body
Tesamorelin stimulates growth-hormone-related signaling rather than acting as a GLP-1 appetite medicine. Egrifta SV’s label reports a short plasma half-life; downstream endocrine effects are a different measurement. Reliable individual onset, peak body-composition benefit and persistence after stopping cannot be predicted from that half-life or an informal cycle.
Benefits & Reported Experiences
The clinically relevant question is reduction of excess visceral abdominal fat in the labeled population, rather than an assurance of losing a particular number of pounds. A visible appearance change cannot by itself establish broader health benefit. The label also notes that long-term cardiovascular safety has not been established.
Side Effects & Risks
Important label concerns include elevated IGF-1, glucose intolerance, fluid retention and hypersensitivity. Active malignancy and specified pituitary problems are among the selection issues. These considerations deserve a provider’s review rather than reassurance based on an informal “gentle peptide” description or an attractive body-composition photo.
Delivery Options
The approved products use subcutaneous administration under product-specific instructions. This article does not provide preparation or reconstitution tutorials. Seine Bio does not offer self-reconstitution powders. A route described in a label is educational context, not confirmation that a listed formulation is available or suitable through this site.
Product Quality & Storage
For Egrifta SV, the label specifies room-temperature storage at 20–25°C and protection from light in its original box. Other formulations need their own instructions. Confirm the precise product and pharmacy labeling; do not borrow storage rules from a research vial, another Egrifta version or a different hormone-related medicine.
Combinations & Interactions
Combining tesamorelin with growth hormone, a secretagogue or metabolic medicines creates additional questions beyond its labeled evidence. Informal stacks do not establish better outcomes or a safe timing scheme. The care team should evaluate total endocrine exposure, concurrent HIV treatment and condition-specific monitoring rather than a community pairing list.
Talking With Your Provider
A useful consultation starts with whether HIV-associated lipodystrophy or another condition explains the concern. Your HIV clinician or appropriate specialist should coordinate any treatment decision. If the goal is general weight management, discuss established options for that goal instead of assuming tesamorelin’s specific approval supplies a broad wellness indication.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is available only where lawful for the specific substance and patient. Approved finished medicines may also be dispensed by licensed non-compounding pharmacies; this disclaimer does not establish access to any investigational product.
Questions about what you read?
Explore the research library Create a free account
Educational information only. A free account lets you request review of your care goals. This profile does not establish availability, clinical suitability or access to the named compound.
Explore clinically appropriate options with a licensed provider. Inquiry does not guarantee a prescription, research-program acceptance or access to a particular substance.
Questions worth bringing to your appointment.
- Are there alternatives that address my goal?
- If treatment is appropriate, what monitoring and follow-up would I need?
- Could my health history or current medicines change the risks?
A clinician may recommend a different option—or no medication—after assessing your individual circumstances.
Saved discussion topics 0
Save topics you would like to discuss with your healthcare provider. Saving is an expression of interest, not a treatment request or medical recommendation.
Saved only in this browser, on this device—not in a patient account. Other people using this browser may see your list. Clear it when using a shared device. This list is not sent to our team.
Bring your curiosity. Start a conversation.
Create a free account to request review and manage purchases. Paid membership is optional. Clinical review and authorization still apply where required, and any separate service charges are shown before you agree to pay.
Create a free account ↗This educational information is free to read. Create a free account to request review of your care goals. Neither an account nor paid membership guarantees a prescription, access to the named compound or research enrollment.
Educational profile · U.S. context · October 7, 2026. This page does not provide personalized medical advice, dosing, or injection instructions.
Bring your saved topics to your care team.
Members can select up to five favorites and send a message for review. Your saved list stays in this browser until you choose what to submit.
Choose saved topics for review →